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MicroRNA (miRNA) are an important class of non-coding RNA which function as post-
transcriptional regulators of gene expression in cells, repressing and ﬁne-tuning protein
output. Prolonged seizures (status epilepticus, SE) can cause damage to brain regions
such as the hippocampus and result in cognitive deﬁcits and the pathogenesis of epilepsy.
Emerging work in animal models has found that SE produces select changes to miRNAs
within the brain. Similar changes in over 20 miRNAs have been found in the hippocampus
in two or more studies, suggesting conserved miRNA responses after SE. The miRNA
changes that accompany SE are predicted to impact levels of multiple proteins involved
in neuronal morphology and function, gliosis, neuroinﬂammation, and cell death. miRNA
expression also displays select changes in the blood after SE, supporting blood genomic
proﬁling as potential molecular biomarkers of seizure-damage or epileptogenesis. Intrac-
erebral delivery of chemically modiﬁed antisense oligonucleotides (antagomirs) has been
shown to have potent, speciﬁc and long-lasting effects on brain levels of miRNAs.Targeting
miR-34a, miR-132 and miR-184 has been reported to alter seizure-induced neuronal death,
whereas targeting miR-134 was neuroprotective, reduced seizure severity during status
epilepticus and reduced the later emergence of recurrent spontaneous seizures. These
studies support roles for miRNAs in the pathophysiology of status epilepticus and miRNAs
may represent novel therapeutic targets to reduce brain injury and epileptogenesis.
Keywords: argonuate, dicer, epilepsy, epileptogenesis, hippocampal sclerosis, miRNA, non-coding RNA, RNA
induced silencing complex
INTRODUCTION
A prolonged, non-terminating seizure (status epilepticus, SE) is
a neurological emergency that has potential to cause irreversible
brain damage. Uncovering the molecular mechanisms by which
seizures transition into an uninterrupted state and elucidating
the downstream consequence of such seizures on the brain are
important if we are to understand and improve treatment of
this devastating condition. MicroRNA (miRNA) have recently
been implicated in the pathophysiology of SE and their expres-
sional responses, targets and mechanisms represent a new focus
of research in this ﬁeld with potential to better understand the
condition, identify novel therapeutics, and develop diagnostic
biomarkers.
STATUS EPILEPTICUS
Seizures are the result of abnormal, synchronous discharges of
groups of neurons in the brain. Most epileptic seizures are self-
terminating, often ending within a minute or less (Chen and
Wasterlain, 2006). This is thought to be due to homeostatic
mechanisms including inactivation of ion channels, build up of
the anticonvulsant adenosine within the extracellular space, the
anti-excitatory effect of tissue acidosis, and other changes (Lado
and Moshe, 2008; Loscher and Kohling, 2010). However, some
seizures do not self-terminate. This can result in the development
of SE, which is variously deﬁned by duration, often as 30 min
of continuous seizure activity or two or more seizures without
complete recovery in between. SE can follow drug withdrawal
in patients with epilepsy but also occurs due to a myriad of other
factors includingCNS infection (Tatum Iv et al., 2001). Themolec-
ular mechanisms underlying the transition from seizure to SE
are poorly understood, but may involve loss of surface receptors
for the inhibitory neurotransmitter γ-amino butyric acid (GABA;
Wasterlain et al., 2009).
The threshold of impending SE is deﬁned operationally as
over 5 min of continuous seizure activity (Chen and Wasterlain,
2006). Such patients require urgent care. Current treatment is with
anticonvulsants such as lorazepam or midazolam (intravenous or
intramuscular) or certain anti-epileptic drugs including pheny-
toin (Rossetti and Lowenstein, 2011; Silbergleit et al., 2012). If
SE persists, additional combinations may be necessary including
intravenous pentobarbital or the anesthetic propofol (Rossetti and
Lowenstein, 2011). There is recent clinical evidence supporting
the use of theN-methyl-D-aspartate (NMDA) receptor antagonist
ketamine (Gaspard et al., 2013; Synowiec et al., 2013).
Status epilepticus has the capability of causing profound brain
damage. The central mechanism of seizure-induced neuronal
injury is glutamate-mediated excitotoxicity but there is also an
important contribution from apoptosis-associated signaling path-
ways (Meldrum, 1991; Fujikawa, 2006; Engel and Henshall, 2009).
Status epilepticus also produces synaptic reorganization, gliosis,
inﬂammation, blood-brain barrier (BBB) damage, and lasting
changes to excitability (Coulter, 1999;Vezzani et al., 2011). Despite
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major progress, there remains a need to further improve our
understanding of the pathophysiologic mechanisms of SE and
explore novel approaches to treatment that may better inter-
rupt SE (particularly pharmacoresistant SE) and prevent long-
term deleterious consequences (e.g., provide neuroprotection and
anti-epileptogenesis).
SE TRIGGERS LARGE-SCALE CHANGES IN EXPRESSION OF
PROTEIN-CODING GENES
Status epilepticus results in large-scale changes to expression of
genes within affected brain regions such as the hippocampus.
The most recent microarray analyses in animal models that fea-
tured genome-wide coverage found changes to over 1000 genes
after SE (Gorter et al., 2006; Jimenez-Mateos et al., 2008; Lauren
et al., 2010). Affected biological processes includemetabolism, sig-
naling, transport, immune response, transcriptional regulation,
cytoskeleton, glial function, neuronal death, and extracellu-
lar matrix organization (Lukasiuk and Pitkanen, 2007; Wang
et al., 2010; Pitkanen and Lukasiuk, 2011a). There has been
recent progress in identifying transcription factors driving up-
and down-regulation of protein-coding genes after SE, includ-
ing Activating transcription factor 5 (ATF5; Torres-Peraza et al.,
2013), CCAAT/enhancer-binding protein homologous protein
(CHOP; Engel et al., 2013b), Neuron restrictive silencing fac-
tor (NRSF/RE1-silencing transcription factor; McClelland et al.,
2011) and Nuclear factor erythroid 2-related factor 2 (Nrf2;
Mazzuferi et al., 2013). Uncovering the regulatory mechanisms
controlling translation of mRNA transcripts represents a largely
unexplored aspect of the molecular pathophysiology of SE.
MicroRNA
MicroRNA represents a potentially critical post-transcriptional
mechanism regulating protein levels after SE. miRNA are an
endogenous class of small (∼23 nt) non-coding RNA that func-
tion to regulate gene expression at a post-transcriptional level
by targeting mRNAs and reducing protein production (Bartel,
2004). Biogenesis of miRNAs is a highly conserved process which
begins with RNA pol II or III-dependent transcription of a pri-
mary transcript (pri-miRNA;Lee et al., 2004; Borchert et al., 2006).
miRNAs can be transcribed as single units or as part of poly-
cistronic miRNA “clusters”, such as miR-17∼92 (He et al., 2005)
andmiR-379∼410 (Seitz et al., 2004). The pri-miRNA is processed
in the nucleus to a shorter hairpin by the Drosha microprocessor
complex (Lee et al., 2003; Gregory et al., 2004). The resulting pre-
miRNA is exported to the cytoplasm for further processing by
the RNAase III enzyme Dicer. Cleavage of pre-miRNA by Dicer
produces the mature miRNA duplex. One strand is selected and
incorporated into the RNA-induced silencing complex (RISC)
while the other strand is typically degraded.
HOW miRNAs WORK
MiRNAs control protein output by binding to speciﬁc, comple-
mentary sequences in target mRNAs of protein-coding genes.
MiRNA binding sites are most often found in the 3′untranslated
region (UTR) but have also been identiﬁed at the 5′end and
within the open reading frame (ORF; Bartel, 2009). In mam-
mals, miRNAs usually do not have complete complementarity to
the mRNA sequence and therefore do not trigger direct cleav-
age of the mRNA as occurs with the RNA interference pathway
activated by short interfering RNAs (Krol et al., 2010). However,
mRNA levels of targets are often reduced bymiRNA targeting (Lim
et al., 2005; Guo et al., 2010). Targeting involves a 7–8 nucleotide
“seed” region within the 5′ end of the miRNA binding to the
mRNA via Watson–Crick base-pairing, followed by a variable
number of further binding sites (Bartel, 2009; Figure 1A). The
molecular machinery driving this process is the RISC which is
a multi-protein complex, comprising members of the argonaute
family as well as GW182 proteins (Fabian et al., 2010). Ago2
is critical in loading the miRNA and bringing it together with
the mRNA target. The effect of miRNA targeting of a mRNA
can be inhibition of translation or deadenylation and subse-
quent degradation, or both (Fabian et al., 2010). RISCs containing
miRNA and their targets may also be sequestered in processing
(P) bodies, including at synapses, which is reversible, enabling
later release of the mRNA for translation (Cougot et al., 2008;
Saugstad, 2010).
IMPACT OF miRNAs ON PROTEIN LEVELS
There are over 1500 miRNAs in the human genome (miRBase
v19). These are predicted to regulate the levels of at least one
third of translated proteins, although over 60% of protein-coding
genes are predicted to have miRNA regulatory sites (Friedman
et al., 2009). Such extensive control is possible because a sin-
gle miRNA may be capable of targeting perhaps 200 mRNAs.
Not all mRNAs are targets for miRNA, however, and mRNA
sequences with short 3′UTRs often lack miRNA binding sites
meaning they are probably not signiﬁcantly regulated in this
manner. Conversely, mRNAs with tissue-speciﬁc expression or
involved in developmental transitions tend to have longer 3′UTRs
with more potential miRNA regulatory sites and these tran-
scripts may be under potent miRNA control (Ebert and Sharp,
2012). MiRNAs also display cell and tissue-speciﬁc distribution
(Lagos-Quintana et al., 2002; Sempere et al., 2004; Shao et al.,
2010; He et al., 2012). In the brain, a large number of miRNAs
display cell-speciﬁc enrichment that contributes to differentiation
and distinguishes neurons from astrocytes, oligodendrocytes, and
microglia (Jovicic et al., 2013).
The impact of a miRNA on protein levels of its targets is often
only within the twofold range (Baek et al., 2008; Selbach et al.,
2008). This may fall below the level capable of producing a phe-
notype, although under conditions of cell stress limited targeting
may be enough to produce a larger effect. Multi-targeting of a sin-
gle mRNA can producemuch stronger effects, in the 10-fold range
or targeting of multiple mRNAs within the same pathway (Ebert
and Sharp, 2012). Nevertheless, for a given miRNA-mRNA pair-
ing, these variables must be determined experimentally and not
assumed based on bioinformatics predictions alone. A miRNA
strongly predicted to target a particular mRNA may or may not
be in a position to inﬂuence its translation. This is particularly
important when considering the signiﬁcance of miRNA changes
reported in SE studies that analyzed pooled brain regions (e.g.,
whole hippocampus) containing multiple cell types expressing
diverse transcripts and displaying varying degrees of vulnerability
to damage after seizures.
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FIGURE 1 | (A) Cartoon showing the site and mechanism of miRNA
targeting to mRNA. Figure highlights the seven nucleotide “seed” region
critical for miRNA binding to the mRNA target. Additional binding also
determines speciﬁcity and potency. Alignment is facilitated by initial miRNA
loading into the RISC which contains Ago2 and GW182 proteins. Binding
typically occurs within the 3′UTR. The result is either degradation of the
mRNA target or inhibition of translation. (B) Cartoon depicting scheme
whereby miRNAs inﬂuence gene expression after SE. Status epilepticus
results in transcriptional up-regulation of 100s of genes. miRNAs lie
downstream of this and exert inﬂuence over protein production and as a
result, inﬂuence post-injury outcomes such as repair, cell death and
reorganization. Such miRNAs represent potential treatment targets to
interrupt pathogenesis of damage and long-term consequences (e.g.,
hyperexcitability).
NEURONAL ACTIVITY AND miRNA EXPRESSION
A key function of neuronal miRNAs is in regulating synap-
tic plasticity in response to neuronal activity (Schratt, 2009;
McNeill and Van Vactor, 2012). Dendritic spines are major sites
of excitatory communication in the brain and the molecular
mechanisms regulating spine size are important determinants of
learning, memory, and perhaps, seizure thresholds (Rochefort
and Konnerth, 2012). In situ hybridization and other visual-
ization techniques reveal enrichment of several miRNAs within
dendrites, including miR-134 (Schratt et al., 2006) and miR-138
(Siegel et al., 2009) and neuronal depolarization or glutamate
receptor activation results in changes to the expression of these
miRNAs. Components of the RISC are also present within the
synapto-dendritic compartment (Lugli et al., 2005) and certain
dendritically localized miRNAs contain sequences within the pre-
cursor form that are identiﬁed by chaperone proteins which then
shuttle them to the dendrite for later processing to the active
mature form (Bicker et al., 2013). The targets of synapto-dendritic
miRNAs are involved in dendritic morphogenesis and include
p250GAP (by miR-132; Vo et al., 2005; Wayman et al., 2008), Lim
kinase (Limk1), and Pumilio2 (by miR-134; Schratt et al., 2006;
Fiore et al., 2009) and acyl protein thioesterase 1 (by miR-138;
Siegel et al., 2009). This system enables prompt, localized con-
trol of neuronal morphology that is responsive to excitatory input
(McNeill and Van Vactor, 2012).
ALTERED microRNA EXPRESSION FOLLOWING SE
MiRNAs may serve important roles in SE by regulating protein
production during and after seizures, thereby inﬂuencing
hyperexcitability, injury, and repair responses (Figure 1B). Sev-
eral studies have proﬁled miRNA responses in the hippocampus
in the acute wake (≤48 h) of SE (Liu et al., 2010; Hu et al., 2011;
Jimenez-Mateos et al., 2011; Risbud and Porter, 2013). Table 1
provides a summary of these studies, including the SE model and
proﬁling platform. Combined, the four studies reveal increased
expression levels of approximately 100 different miRNAs after
SE while levels of about 200 miRNAs decreased. Although there
are difﬁculties with cross-comparing data derived from differ-
ent platforms and inter-study differences in the models, seizure
severity and timing of sampling, a sub-set of miRNAs changed
expression in at least two proﬁling studies. This includes six up-
regulated miRNAs (miRNAs-21, -30c, -125b, -132, -199a, and
-375) and nine down-regulated miRNAs (miRNAs-10b, -29a, -
98, -181b,c, -374, -381, -450a, and -497; Table 1). In another
study, miR-10b levels were found to be up-regulated after SE
(Jimenez-Mateos et al., 2011). If studies that performed analy-
ses of single miRNAs are also included then this list expands
to include up-regulation of miR-34a, miR-134, and miR-155,
and down-regulation of miR-9, miR-125a, miR-145, and miR-
150 (Hu et al., 2012; Pichardo-Casas et al., 2012; Sano et al.,
2012; Ashhab et al., 2013; Peng et al., 2013). Also, miR-146a
has been consistently found to be upregulated after SE, albeit at
later time points (Aronica et al., 2010; Hu et al., 2012; Omran
et al., 2012). Thus, over 20 miRNAs appear to show conserved
responses to SE. This is likely an under-estimate, however, since
most proﬁling studies had limited spatio-temporal sampling and
incomplete coverage of the rodent miRNAome. The roles of a
selection of the proﬁling-identiﬁed miRNAs potentially relevant
to seizures and brain function are reviewed brieﬂy below. A poten-
tial caveat is that in most cases we do not have direct evidence
that these miRNAs are functional – uploaded to the RISC –
after SE.
CONSERVED miRNAs DETECTED AFTER SE IN PROFILING STUDIES
Among the four studies to have proﬁled miRNA responses to
SE, miR-132 is the most consistently up-regulated miRNA, being
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Table 1 | miRNA proﬁling after status epilepticus.
Reference Platform SE model Time
point(s) (h)
Proﬁled Regulateda Common
Liu et al. (2010) Taqman KA (rat) 24 380 31 (13 Up, 18 Down) Up: miR-21, miR-30c, miR-125b,
miR-132, miR-199a, miR-375
Hu et al. (2011) Microarray PILO (rat) 24 113 26 (19 Up, 7 Down)
Jimenez-Mateos et al. (2011) Taqman KA (mouse) 24 380 33 (21 Up, 12 Down)
Risbud and Porter (2013) Microarray PILO (rat) 4, 48 All 265 (77 Up, 188 Down) Down: miR-10b, miR-29a, miR-98,
miR-181b,c, miR-374, miR-381,
miR-450a, miR-497
Table summarizes the main studies which have proﬁled changes to miRNAs in the ﬁrst 48 h after SE, including the proﬁling platform, animal model of SE, time point,
number of miRNAs studied and the number altered by SE. aNumbers of regulated miRNAs are a guide only – studies differed in terms of what threshold was set for
calling a miRNA “regulated” and the application of statistics and/or correction for multiple comparisons. Of note, in the Liu et al study, if miRNAs regulated by at least
1.5-fold are included, then 60 were regulated, with 21 up-regulated and 38 downregulated. Also, miRNAs “not detected” after SE were considered down-regulated
in Jimenez-Mateos et al. (2011). Box on far right depicts the commonly regulated miRNAs from these studies (same direction in two or more studies). KA, kainic acid;
PILO, pilocarpine.
identiﬁed in 3/4 of the studies (Hu et al., 2011; Jimenez-Mateos
et al., 2011; Risbud and Porter, 2013). Up-regulation of miR-132
was also reported in two other studies that looked at individual
miRNA responses to SE (Nudelman et al., 2010; Peng et al., 2013)
and miR-132 is over-expressed in human temporal lobe epilepsy
(Peng et al., 2013). Increased levels of miR-132 are also present
in Ago2-eluted samples from the hippocampus after experimental
SE, implying it is functional (Jimenez-Mateos et al., 2011).
The role of miR-132 in the brain is increasingly well under-
stood. Expression of miR-132 is associated with synaptogenesis
and a number of miR-132 targets are of potential relevance
to the pathophysiology of SE (see Table 2). Overexpression of
miR-132 in hippocampal neurons in culture was shown to cause
neurite (Vo et al., 2005) and dendritic (Wayman et al., 2008)
sprouting, and increase excitatory currents (Edbauer et al., 2010).
Over-expression of miR-132 in vivo (∼ﬁvefold was achieved)
resulted in an increase in spine density and was associated with
a deﬁcit in novel object recognition task (Hansen et al., 2010).
In contrast, deletion of miR-132 in vivo is associated with
decreased dendritic length and branching (Magill et al., 2010)
and select defects in synaptic transmission (Pathania et al., 2012).
Other predicted targets of miR-132 include MeCP2 (Lusardi
et al., 2010), loss of which promotes cognitive deﬁcits, hyper-
excitability and seizures (Shahbazian et al., 2002). Targeting of
acetylcholinesterase by miR-132 may increase cholinergic tone
and inﬂuence excitability, hippocampal function, or inﬂamma-
tion (Friedman et al., 2007; Shaked et al., 2009; Shaltiel et al.,
2013). The increased hippocampalmiR-132 levels that accompany
Table 2 | miRNAs targeted in status epilepticus.
miRNA Targets Regulatory control Biological function(s) Effect of in vivo silencing
miR-34a Bcl-2, CDK4, SIRT1, Map3k9, Syt p53 (↑), p73 (↑) Apoptosis, neuronal
differentiation
↓ Hippocampal damage, ↓ apoptosis signaling,
no change in SE severity
miR-132 MeCP2, P250GAP, AChE CREB (↑), NRSF (↓) Dendritic spines (shape,
density), ACh breakdown, Gene
silencing
↓ Hippocampal damage, no change in SE
severity
miR-134 Limk1, Pum2, CREB, DCX Mef2 (↑), YY1 (↓) Dendritic spines (shape,
complexity), synaptic plasticity,
differentiation
↓ Hippocampal damage, ↓ SE severity,
↓ epileptic seizures
miR-184 Akt2, Ago2 STAT3 (↑) Apoptosis, interleukin signaling ↑ Hippocampal damage, no change in SE
severity
Table lists the four miRNAs which have been targeted in vivo in SE models. Table also includes examples of some validated miRNA targets of potential relevance to
seizures/epilepsy, examples of their expressional control (transcription factors which act to either increase or decrease levels of the miRNA), examples of established
biological functions and, ﬁnally, the impact of targeting the miRNA using an LNA-antagomir in vivo. AChE, acetylcholinesterase; Ago2, Argonaute 2; Bcl2; B Cell
lymphoma 2; CDK4, cyclin-dependent kinase-4; CREB, cAMP-response element binding protein; DCX, doublecortin; Limk1, Lim-domain kinase 1; Map3k9, mitogen-
activated protein kinase kinase kinase 9; MeCP2, methyl CpG binding protein 2; p250GAP, Rho GTPase activating protein; Pum2; Pumilio2; SIRT1, Sirtuin 1; Syt,
Synaptotagmin; YY1, Yin yang 1.
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SE and are present in epilepsy may, therefore, inﬂuence neu-
ronal morphology and contribute to hyperexcitability or cognitive
dysfunction.
Much less is known about the remaining conserved miRNAs
from the proﬁling studies. Most of the functional studies have
been in cancer, where their targets have been linked to controlling
apoptosis, invasiveness, and cell division. While this may ﬁt with
pathways expected to be regulated after SE, it is likely that some (or
perhaps most) of the brain targets of these miRNAs in the setting
of SE will be different.
Based on available functional studies and known targets,
includingmembers of the Bcl-2 family and p53 pathway, increased
levels of miR-21, miR-125b, and down-regulation of miR-29a and
miR-497 in SE would be expected to have an anti-apoptotic effect
(Chan et al., 2005; Mott et al., 2007; Sathyan et al., 2007; Le et al.,
2009; Park et al., 2009;Yin et al., 2010;Yadav et al., 2011;Amir et al.,
2013). In contrast, down-regulation of miR-10b andmiR-98 in SE
would be predicted to have a pro-apoptotic effect based on their
roles as “oncomirs” (Ma et al., 2007; Ozsait et al., 2010; Foley et al.,
2011;Wang et al., 2011). These miRNAsmay therefore be involved
in the control of apoptosis-associated signaling and regulation of
seizure-induced neuronal death (Bozzi et al., 2011; Henshall and
Engel, 2013).
Members of the miR-181 family have been linked to promot-
ing cell death (Shi et al., 2008) and may control expression of
Bcl-2 family proteins (Ouyang et al., 2012). Astrocytes are particu-
larly enriched in miR-181c, and reduced miR-181b and miR-181c
levels promote astrocyte-derived cytokine responses (Hutchison
et al., 2013). Thus, miR-181, like miR-146a (Iyer et al., 2012), may
negatively regulate inﬂammatory responses in astrocytes after SE.
For the remaining miRNAs down-regulated in at least two pro-
ﬁling studies – miR-374, miR-381, miR-450a – there is little or
no relevant experimental data beyond detection in some cancer
models. Whether these represent novel miRNAs with roles in the
pathogenesis of SE is uncertain but could be explored in future
studies.
CONTROL OF microRNA EXPRESSION AFTER SE
Although we have an increasingly expansive picture of whichmiR-
NAs change after SE and inwhat direction,we know little about the
mechanisms controlling miRNA expression itself. No studies have
directly explored miRNA regulatory control in SE, however the
transcriptional control mechanism for some SE-regulated miR-
NAs is understood (Table 2). Expression of miR-34a is controlled
by p53 (Chang et al., 2007; Raver-Shapira et al., 2007) as well as
p73 (Agostini et al., 2011), and an inhibitor of p53 prevented
miR-34a upregulation after SE (Sano et al., 2012). Expression of
miR-132 is regulated by CREB, a stress-activated transcription
factor that promotes neuronal survival (Lee et al., 2009). Some
CREB-mediated effectsmay be pro-epileptogenic. Consistent with
this, mice with decreased CREB levels develop fewer sponta-
neous seizures followingpilocarpine-inducedSE (Zhuet al.,2012).
For miR-134, regulatory control is activity-dependent and driven
by Mef2 (Fiore et al., 2009). miRNAs have also been identi-
ﬁed under control of the transcriptional repressor NRSF. NRSF
is implicated in the epigenetic silencing of multiple genes after
SE and interference in NRSF function can recover expression
and function of genes whose down-regulation is implicated in
epileptogenesis (McClelland et al., 2011). MiR-124 is a known
NRSF target that is involved in deﬁning the neuronal pheno-
type. Levels of miR-124 have been reported to both increase (Peng
et al., 2013) and decrease (Risbud and Porter, 2013) following SE
in rats. These transcription factors and others may exert their
inﬂuence on the post-SE molecular environment by modulating
expression of miRNAs under their control. Their targeting rep-
resents potential approaches for modulating miRNA expression
in SE.
Time-course studies have noted abrupt increases in miRNA
expression, with rapid turn-on followed by restitution to base-
line or lower levels after SE (McKiernan et al., 2012; Sano et al.,
2012). This type of precise, dynamic response is reminiscent of
miRNA responses during brain development (Krichevsky et al.,
2003) and after other CNS insults (Lusardi et al., 2010), and sup-
ports tight transcriptional control of the spatiotemporal induction
of miRNAs. This has implications for studies where only a single
time point has been used because in the absence of a complete
time course, erroneous conclusions may be drawn about the full
response of a miRNA to SE.
THERAPEUTIC miRNA TARGETING IN SE
Targeting miRNAs for therapeutic beneﬁt is gaining increasing
attention in multiple ﬁelds (Brown and Naldini, 2009; Stenvang
et al., 2012). If miRNAs exert signiﬁcant inﬂuence over processes
involved in either seizure generation or the pathophysiological
consequences of SE then miRNA targeting may have therapeutic
potential. Delivery of a miRNA inhibitor or replenishment of an
otherwise lost miRNA (e.g., via a miRNA mimic) could alter the
excitability of the brain leading to less severe seizures or mitigate
the downstream consequences leading to neuroprotection.
Brain-expressed miRNAs represent challenging targets for
experimental and therapeutic modulation in vivo. First, miRNAs
display cell-speciﬁc expression and tight transcriptional regula-
tion along with their potential for multi-targeting, the control
of which is still poorly understood. This means that delivery of
an inhibitor or mimic may require careful timing and the means
to control where it goes in the brain. Second, small molecules
(e.g., <1000 Da) do not yet exist that selectively target miR-
NAs, although small molecules have been identiﬁed which alter
miRNA biogenesis (Shan et al., 2008; Melo et al., 2011). A lead-
ing approach is to use antisense oligonucleotides (antagomirs;
Stenvang et al., 2012). Modiﬁcations such as locked nucleic acid
(LNA; Wahlestedt et al., 2000) make these potent and selective
miRNA inhibitors and further modiﬁcations such as placement of
cholesterol (Krutzfeldt et al., 2005) or other tags [e.g., penetratin
peptide (Schratt et al., 2006)] facilitate cell entry. Studies show that
for a miRNA to be inhibited the antagomir must be in several fold
excess (Ebert et al., 2007). The mechanism by which antagomirs
reduce miRNA function appears to differ depending on the chem-
istry of the molecules, and includes activation of degradation
mechanisms and sequestration as a heteroduplex (Stenvang et al.,
2012). Shorter sequences, so-called “tiny LNAs” which share
common seed regions of miRNA families may enable blockade
of multiple miRNA members and further potentiate targeting
efﬁcacy (Obad et al., 2011). A potentially attractive quality of
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antagomir targeting of miRNAs is prolonged suppression of the
miRNA. Silencing of miRNAs by antagomirs has been reported to
last several weeks in the periphery (Krutzfeldt et al., 2005; Elmen
et al., 2008) and after injection into the brain (Jimenez-Mateos
et al., 2012). Another challenge is that antagomirs do not cross an
intact BBB (Krutzfeldt et al., 2005). Todate, this has beenovercome
by direct intracerebroventricular microinjection of antagomirs
(Jimenez-Mateos et al., 2011;Huet al., 2012; Jimenez-Mateos et al.,
2012; McKiernan et al., 2012; Sano et al., 2012). However, BBB
integrity is disrupted by seizures (Marchi et al., 2012) therefore
systemic injection may be sufﬁcient to deliver antagomirs into the
brain after SE. If the site of BBB disruption is limited to the area
of pathologic activity then brain penetration may restrict deliv-
ery to the site of injury with minimal effects elsewhere in the
brain. Alternatively, strategies can be used to temporarily breach
the BBB (Campbell et al., 2008), or antagomirs can be given via
intra-nasal delivery (Jimenez-Mateos et al., 2012) or encapsulated
in a nanoparticle or exosome (Alvarez-Erviti et al., 2011).
Clinical trials are now underway using antagomirs for non-
CNS conditions. Miravirsen targets miR-122, which is involved
in hepatitis C virus replication and miravirsen was shown to be
safe and effective in patients (Janssen et al., 2013). This raises the
possibility of using miRNA-based therapeutics for other diseases,
including CNS applications (Brown and Naldini, 2009; Stenvang
et al., 2012).
miRNA TARGETING IN SE
Four miRNAs have been targeted in vivo in experimental mod-
els of SE using antagomirs (Table 2). The ﬁrst to be targeted
was miR-132 (Jimenez-Mateos et al., 2011). Intracerebroventricu-
lar injection of an LNA-modiﬁed antagomir targeting miR-132
reduced hippocampal levels of miR-132 when measured 24 h
later in mice. Animals in which miR-132 had been silenced and
then subjected to SE were found to have signiﬁcantly less dam-
age to the CA3 subﬁeld of the hippocampus (Jimenez-Mateos
et al., 2011). No effects of the antagomirs were reported on seizure
severity. The mechanism of the protection is unknown and while
miR-132 was conﬁrmed in other experiments to be increased
in the RISC, the mRNA targets in the RISC were not explored
(Jimenez-Mateos et al., 2011). Whether the neuroprotection has
any functional effects is unknown as cognitive tests have not yet
been performed. However, a similar degree of neuroprotection in
the samemodel was associated with fewer spontaneous seizures in
long-term EEG monitoring studies (Jimenez-Mateos et al., 2008;
Engel et al., 2010).
Silencing of two other miRNAs has been reported to alter
seizure-induced neuronal death without affecting the severity of
SE (Table 2). MiR-34a is another miRNA whose up-regulation
has been reported in multiple models (Hu et al., 2012; Sano et al.,
2012). Increased miR-34a levels promote apoptosis via suppress-
ing anti-apoptotic proteins including Bcl-2 (Hermeking, 2010).
However, the pro-apoptotic effect of miR-34a in neurons has
been questioned (Agostini et al., 2011). More recently, miR-34a
was shown to be a positive and negative regulator of neuronal
differentiation, targeting synaptotagmin-1 (Agostini et al., 2011),
and Numb1 (Fineberg et al., 2012). Inhibition of miR-34a using
antagomir infusions into the ventricle of rodents was reported to
reduce seizure-induced neuronal death in one study (Hu et al.,
2012), but not in another (Sano et al., 2012). In contrast, tar-
geting miR-184, a miRNA up-regulated by a protective episode
of brief, non-harmful seizures, resulted in increased susceptibil-
ity to seizure-induced neuronal death in mice (McKiernan et al.,
2012). Again, seizure severity was not affected. This supports miR-
184 having protective effects against seizure-damage, although no
candidate targets of this miRNA are obvious to explain this action
(Table 2). Together with results of miR-132 and miR-34a, these
studies reveal miRNAs as potential targets for modulating cell
death after SE.
MiR-134 is another activity-regulated miRNA that has been
found to be upregulated after SE in kainate and pilocarpine mod-
els of SE (Jimenez-Mateos et al., 2011, 2012; Peng et al., 2013).
Levels of miR-134 were also conﬁrmed to be increased in the
RISC in Ago2 pull down experiments after SE and there were
lower protein levels of two validated targets (Jimenez-Mateos et al.,
2012). Targeting miR-134 using intracerebroventricular injec-
tions of LNA-modiﬁed antagomirs produced silencing of the
miRNA lasting several weeks. When mice were injected with
the antagomirs 24 h before SE, the resulting seizure severity was
strongly reduced. Indeed, the seizure suppression was qualita-
tively similar to the effect of the anticonvulsant lorazepam in the
same model (Jimenez-Mateos et al., 2012). Hippocampal dam-
age in these antagomir pre-treatedmice was also strongly reduced,
although thismay have been secondary to the anticonvulsant effect
rather than a direct neuroprotective action.
In further experiments, the authors tested the effect of the
antagomirs on the development of epilepsy. Antagomirs were
injected 1 h after SE, ensuring the initial brain insult was simi-
lar between antagomir and scrambled-control SE mice. In EEG
and video monitoring of the mice the antagomir-injected ani-
mals displayed∼90% fewer spontaneous seizures during the next
month (Jimenez-Mateos et al., 2012). Seizure frequency remained
reduced 2 months later indicating, presumably, a permanent pro-
tective effect. Chronic pathologic changes to the hippocampus
including progressive neuronal loss, gliosis, and synaptic reor-
ganization were also reduced (Jimenez-Mateos et al., 2012). The
mechanism by which silencing miR-134 produces these strong
anti-seizure effects is unknown, although in vitro experiments
suggested they may be Limk1-dependent (Jimenez-Mateos et al.,
2012). These ﬁndings suggest antagomirs targeting this miRNA
could have neuroprotective and disease-modifying effects which
might be a new therapeutic strategy for SE.
miRNAs AS BIOMARKERS OF SEIZURE-DAMAGE AND
EPILEPTOGENESIS
MiRNAs have been recognized as having potential as non-invasive
biomarkers (Scholer et al., 2010; de Planell-Saguer and Rodicio,
2011). Unique expression proﬁles of miRNAs have been reported
in blood and other bioﬂuids in animal models and patients and
thesemay be useful as diagnostics, helping to discriminate between
diseases with a similar clinical presentation, provide better strat-
iﬁcation of patients, predicting disease course, and responses to
therapy. Bioﬂuid miRNA proﬁles could also have applications in
toxicology and as markers of tissue damage. Part of their attrac-
tion lies with the conserved and widespread function of miRNAs
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in cell physiology and disease but there are also physico-chemical
properties of miRNAs thatmake them suitable biomarkers. Unlike
most other forms of RNA, miRNAs are remarkably stable in
bioﬂuids, remaining detectable in serum for weeks and they
are also resistant to freeze-thaw and pH changes (Chen et al.,
2008; McDonald et al., 2011; Blondal et al., 2013). The stability is
attributable, at least in part, to binding toAgo2 (Arroyo et al., 2011;
Turchinovich et al., 2011) andpresence inmembrane-enclosed cir-
culatingmicrovesicles such as exosomes (Hunter et al., 2008; Gallo
et al., 2012).
There is an emerging consensus that biomarkers would be
useful diagnostics in epilepsy (Pitkanen and Lukasiuk, 2011b;
Simonato et al., 2012; Engel et al., 2013a). Molecular biomark-
ers of SE could be used to gauge insult severity, prognosis, and
inform the choice of anticonvulsants or administration of anti-
epileptogenic treatments, were they to become available. Evidence
is emerging that miRNA signatures in bioﬂuids can distinguish
between different forms of neurological disease or acute brain
injuries (Rong et al., 2011; Balakathiresan et al., 2012; Baraniskin
et al., 2012; Haghikia et al., 2012). To date only a single study has
looked at miRNA changes in the blood following SE (Liu et al.,
2010). This revealed that kainate-induced seizures in rats pro-
duce uniquemiRNA expression proﬁles in blood that are different
from those produced by other acute neurological injuries, includ-
ing stroke, and hemorrhage (Liu et al., 2010). The study reported
up-regulation of 15 miRNAs and decreased levels of 43 miRNAs
in blood, although none passed correction for multiple compar-
isons (Liu et al., 2010). Nevertheless, this supports bioﬂuidmiRNA
changes as a source of molecular biomarkers of SE. Notably, a
number of the commonly regulatedmiRNAs identiﬁed in the hip-
pocampus in proﬁling studies are found in serum and plasma,
including miR-29a, miR-125b, andmiR-375 (Blondal et al., 2013).
Just as signiﬁcantly, several miRNAs increased by SE in the hip-
pocampus are not normally present in these bioﬂuids, including
miR-132 and miR-134 (Blondal et al., 2013), supporting their
detection post-SE as a potential biomarker of seizures or injury.
REMAINING CHALLENGES
What are some of the future challenges? There is a need to
identify the targets of seizure-regulated miRNAs. This could be
achieved using techniques such as HITS-CLIP, whereby RISC-
loaded RNAs are cross-linked to proteins followed by Ago2-
immunoprecipitation and sequencing (Chi et al., 2009). Knowl-
edge of the in vivo targets of miRNAs in SEmodels would also lead
to better understanding of the mechanisms by which antagomirs
produce their effects. The speciﬁcity of antagomirs in the brain
has yet to be established, although some studies have looked at
potential off-target effects (Jimenez-Mateos et al., 2011, 2012).
Future studies should explore ways to deliver antagomirs via sys-
temic routes while also including assessment of cognitive effects
of miRNA silencing. This is particularly relevant for miR-132 and
miR-134 because these directly regulate dendritic spines and small
changes to levels of miRNA regulating dendritic spines have been
found to produce behavioral phenotypes (Hansen et al., 2010).
There are several directions that could be taken to explore the
potential of miRNAs as biomarkers in SE. For example, com-
paring proﬁles in different bioﬂuids or between different models,
and identifying miRNAs with predictive value for epileptogenesis.
More clinical data are needed. For example, are miRNAs proﬁles
in the brain or bioﬂuids altered following SE in patients?
Several of the other commonly regulated miRNAs have yet to
be targeted in animal models but likely represent focuses of the
future. Combinations of miRNA targeting or delivery could offer
ways to more completely block deleterious consequences of SE
such as epileptogenesis. Experiments could also explore whether
antagomirs can have effects on already established epilepsy. Can a
disease-modifying effect be produced once epilepsy is established?
Clearly, miRNA functions are directly relevant to seizure
thresholds, but clinical applications of miRNA-based therapeutics
for SE would most likely be as disease-modifying post-treatments
rather than acute anticonvulsants. This is because antagomirs take
time to producemiRNAknockdown andmeasurable effects on the
de-repressed targets. This means they are not realistic prospects
for stopping SE, although perhaps therewould be an application in
super-refractory SE (Shorvon, 2011). Nevertheless, faster or more
efﬁcient targeting toolsmay emerge or indeedwemay simply iden-
tify better miRNA targets or ﬁnd ways to target the proteins under
their control.
SUMMARY
MiRNAs represent a major additional layer of gene expres-
sion control in SE, regulating protein levels within cells in the
seizure-damaged brain. As functional studies begin to explore the
importance of individual miRNAs in SE we are seeing inﬂuences
on neuronal death, excitability, gliosis, and neuroinﬂammation.
Many or even most processes dysregulated after SE may be con-
trolled to some degree by miRNA expression. The arrival of
miRNA-based inhibitors in clinical trials in other diseases herald
translation to the clinic that may eventually also be possible for
SE. Translation will be facilitated by focusing on the most critical
miRNAs, identifying the molecular targets of miRNAs altered by
SE and exploring antagomir delivery routes. Last, miRNAs repre-
sent an interesting class of biomarker that may have applications
for tracking the severity of injury after SE and whether or not a
patient is at risk of long-term consequences such as development
or exacerbation of epilepsy.
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